



Clinical trial results:

Assessment of the efficacy of POLYGYNAX® in the empirical treatment of infectious vaginitis

International, multicentre, randomised, double-blind, parallel group study, comparative versus miconazole

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2014-001759-22 |
| Trial protocol | FR CZ SK |
| Global end of trial date | 25 August 2016 |

Results information

| | |
|--------------------------------|--------------|
| Result version number | v1 (current) |
| This version publication date | 15 July 2018 |
| First version publication date | 15 July 2018 |

Trial information

Trial identification

| | |
|-----------------------|-----------|
| Sponsor protocol code | PGX401-11 |
|-----------------------|-----------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT02515656 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Laboratoire Innotech International |
| Sponsor organisation address | 22 avenue Aristide Briand, ARCUEIL, France, 94111 Cedex |
| Public contact | Medical Affairs Department, Laboratoire Innotech International, 0033 146152800, |
| Scientific contact | Medical Affairs Department, Laboratoire Innotech International, 0033 146152800, |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|----------------|
| Analysis stage | Final |
| Date of interim/final analysis | 25 August 2016 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 25 August 2016 |
| Global end of trial reached? | Yes |
| Global end of trial date | 25 August 2016 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study is to demonstrate the superior clinical efficacy of POLYGYNAX® at the End of Treatment Visit (Visit 2 / D15 or Premature Discontinuation Visit if any) compared to miconazole in the empirical treatment of infectious vaginitis

Protection of trial subjects:

Not applicable

Background therapy: -

Evidence for comparator: -

| | |
|---|-------------------|
| Actual start date of recruitment | 07 September 2015 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects**Subjects enrolled per country**

| | |
|--------------------------------------|---------------------|
| Country: Number of subjects enrolled | Slovakia: 131 |
| Country: Number of subjects enrolled | Czech Republic: 318 |
| Country: Number of subjects enrolled | France: 148 |
| Country: Number of subjects enrolled | Serbia: 61 |
| Worldwide total number of subjects | 658 |
| EEA total number of subjects | 597 |

Notes:

Subjects enrolled per age group

| | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 658 |
| From 65 to 84 years | 0 |

| | |
|-------------------|---|
| 85 years and over | 0 |
|-------------------|---|

Subject disposition

Recruitment

Recruitment details:

Recruitment period: 07 Sep 2015 to 03 Aug 2016.

Countries involved: France - Czech Republic - Slovakia - Serbia

Pre-assignment

Screening details: -

Pre-assignment period milestones

| | |
|------------------------------|-----|
| Number of subjects started | 658 |
| Number of subjects completed | 658 |

Period 1

| | |
|------------------------------|--|
| Period 1 title | overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor, Assessor |

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|------------------|-----------|
| Arm title | Polygynax |
|------------------|-----------|

Arm description: -

| | |
|--|-----------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Polygynax |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Vaginal capsule, soft |
| Routes of administration | Vaginal use |

Dosage and administration details:

Nystatin (100 000 IU) + Neomycin sulphate (35 000 IU) + Polymyxin B sulphate (35 000 IU).

One vaginal capsule once daily for 12 consecutive days.

| | |
|------------------|--------------------|
| Arm title | Miconazole+Placebo |
|------------------|--------------------|

Arm description: -

| | |
|--|-----------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | Miconazole+Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Vaginal capsule, soft |
| Routes of administration | Vaginal use |

Dosage and administration details:

Miconazole nitrate (400mg) + Placebo

One Miconazole capsule once daily for 3 consecutive days then one placebo capsule once daily for 9 consecutive days.

| Number of subjects in period 1 | Polygynax | Miconazole+Placebo |
|--|-----------|--------------------|
| Started | 326 | 332 |
| Completed | 270 | 261 |
| Not completed | 56 | 71 |
| Consent withdrawn by subject | 1 | 5 |
| Screening failure | 1 | - |
| Adverse event, non-fatal | 1 | 3 |
| Use of treatment not allowed | - | 1 |
| Lost to follow-up | - | 2 |
| Lack of efficacy | 25 | 39 |
| STI detected from the first vaginal sample | 24 | 19 |
| Final visit not done | 4 | 2 |

Baseline characteristics

Reporting groups

| | |
|--------------------------------|--------------------|
| Reporting group title | Polygynax |
| Reporting group description: - | |
| Reporting group title | Miconazole+Placebo |
| Reporting group description: - | |

| Reporting group values | Polygynax | Miconazole+Placebo | Total |
|--|-----------|--------------------|-------|
| Number of subjects | 326 | 332 | 658 |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 326 | 332 | 658 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age continuous Units: years | | | |
| arithmetic mean | 34.26 | 33.51 | |
| standard deviation | ± 10.18 | ± 9.97 | - |
| Gender categorical Units: Subjects | | | |
| Female | 326 | 332 | 658 |
| Male | 0 | 0 | 0 |

Subject analysis sets

| | |
|--|--------------------|
| Subject analysis set title | FAS population |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | |
| <p>The FAS population is defined as all randomised patients excluding (as allowed by ICH E9):</p> <ul style="list-style-type: none"> • Patients who did not take at least one dose of the study medication • Patients who present an STI (trichomoniasis; gonococcal and chlamydial infections) detected from the vaginal sample taken before randomisation at the Baseline Visit (Visit 1 / D1). • Patients without post-randomisation data. | |
| Subject analysis set title | PPS population |
| Subject analysis set type | Per protocol |
| Subject analysis set description: | |
| <p>The PPS population consists of all patients of the FAS without any major protocol deviation. This is the set of patients who participated in the study as intended. Before locking the data base, the precise reasons for excluding patients from the PP data set were fully defined and documented during a blind review meeting.</p> | |
| Subject analysis set title | mPPS Population |
| Subject analysis set type | Sub-group analysis |

Subject analysis set description:

The mPPS population consists of all patients of the FAS without any major protocol deviation except deviations about randomization process. This population was used for an additional sensitivity analysis on the PPS to document the influence of including or excluding these patients with deviations from the randomisation schedule.

| | |
|----------------------------|-------------------|
| Subject analysis set title | Safety Population |
| Subject analysis set type | Safety analysis |

Subject analysis set description:

The SS population comprises all enrolled patients in the study, who have been administered at least one capsule of study drug.

| Reporting group values | FAS population | PPS population | mPPS Population |
|---|----------------|----------------|-----------------|
| Number of subjects | 611 | 552 | 585 |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 611 | 552 | 585 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age continuous Units: years | | | |
| arithmetic mean | 34.21 | 34.33 | 34.16 |
| standard deviation | ± 10.11 | ± 10.14 | ± 10.03 |
| Gender categorical Units: Subjects | | | |
| Female | 611 | 552 | 585 |
| Male | 0 | 0 | 0 |

| Reporting group values | Safety Population | | |
|---|-------------------|--|--|
| Number of subjects | 653 | | |
| Age categorical Units: Subjects | | | |
| In utero | 0 | | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | | |
| Newborns (0-27 days) | 0 | | |
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 0 | | |
| Adults (18-64 years) | 653 | | |
| From 65-84 years | 0 | | |
| 85 years and over | 0 | | |
| Age continuous Units: years | | | |
| arithmetic mean | 33.94 | | |
| standard deviation | ± 10.09 | | |

| | | | |
|--------------------|-----|--|--|
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 653 | | |
| Male | 0 | | |

End points

End points reporting groups

| | |
|-----------------------|-----------|
| Reporting group title | Polygynax |
|-----------------------|-----------|

Reporting group description: -

| | |
|-----------------------|--------------------|
| Reporting group title | Miconazole+Placebo |
|-----------------------|--------------------|

Reporting group description: -

| | |
|----------------------------|----------------|
| Subject analysis set title | FAS population |
|----------------------------|----------------|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

The FAS population is defined as all randomised patients excluding (as allowed by ICH E9):

- Patients who did not take at least one dose of the study medication
- Patients who present an STI (trichomoniasis; gonococcal and chlamydial infections) detected from the vaginal sample taken before randomisation at the Baseline Visit (Visit 1 / D1).
- Patients without post-randomisation data.

| | |
|----------------------------|----------------|
| Subject analysis set title | PPS population |
|----------------------------|----------------|

| | |
|---------------------------|--------------|
| Subject analysis set type | Per protocol |
|---------------------------|--------------|

Subject analysis set description:

The PPS population consists of all patients of the FAS without any major protocol deviation. This is the set of patients who participated in the study as intended. Before locking the data base, the precise reasons for excluding patients from the PP data set were fully defined and documented during a blind review meeting.

| | |
|----------------------------|-----------------|
| Subject analysis set title | mPPS Population |
|----------------------------|-----------------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Sub-group analysis |
|---------------------------|--------------------|

Subject analysis set description:

The mPPS population consists of all patients of the FAS without any major protocol deviation except deviations about randomization process. This population was used for an additional sensitivity analysis on the PPS to document the influence of including or excluding these patients with deviations from the randomisation schedule.

| | |
|----------------------------|-------------------|
| Subject analysis set title | Safety Population |
|----------------------------|-------------------|

| | |
|---------------------------|-----------------|
| Subject analysis set type | Safety analysis |
|---------------------------|-----------------|

Subject analysis set description:

The SS population comprises all enrolled patients in the study, who have been administered at least one capsule of study drug.

Primary: Clinical treatment efficacy assessed by the investigator

| | |
|-----------------|---|
| End point title | Clinical treatment efficacy assessed by the investigator ^[1] |
|-----------------|---|

End point description:

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Visit 2 / Day 15

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The procedure for the primary endpoint statistical analysis at the final analysis is: the proportion of patients with a success according to investigator clinical assessment was computed and compared between treatment groups using a test for the difference between two binomial proportions in SAS SEQTEST procedure.

| End point values | Polygynax | Miconazole+Placebo | FAS population | |
|-----------------------------|-----------------|--------------------|----------------------|--|
| Subject group type | Reporting group | Reporting group | Subject analysis set | |
| Number of subjects analysed | 302 | 309 | 611 | |
| Units: % Success | | | | |
| number (not applicable) | 91.1 | 86.7 | 88.9 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change in vaginal discharge and in each associated clinical symptoms reported by the patient in the diary

| | |
|-----------------|---|
| End point title | Change in vaginal discharge and in each associated clinical symptoms reported by the patient in the diary |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From visit 1 / D1 to visit 2 / D14

| End point values | Polygynax | Miconazole+Placebo | | |
|--|------------------------|------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 302 | 309 | | |
| Units: mm | | | | |
| least squares mean (confidence interval 95%) | | | | |
| Vaginal Discharge | 31.43 (29.94 to 32.91) | 29.54 (28.07 to 31.01) | | |
| Vaginal Burning | 27.89 (26.66 to 29.12) | 27.03 (25.81 to 28.25) | | |
| Vaginal Pain | 16.93 (15.86 to 18.01) | 17.17 (16.1 to 18.24) | | |
| Vaginal Irritation | 29.37 (28.06 to 30.67) | 28.79 (27.51 to 30.08) | | |
| Combined clinical symptoms | 28.96 (26.79 to 31.14) | 28.2 (26.04 to 30.35) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Clinical treatment efficacy at end of study

| | |
|-----------------|---|
| End point title | Clinical treatment efficacy at end of study |
|-----------------|---|

End point description:

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Visit 3 / Day 22 | |

| End point values | Polygynax | Miconazole+Placebo | FAS population | |
|-----------------------------|-----------------|--------------------|----------------------|--|
| Subject group type | Reporting group | Reporting group | Subject analysis set | |
| Number of subjects analysed | 302 | 309 | 611 | |
| Units: % Success | | | | |
| number (not applicable) | 84.8 | 82.5 | 83.7 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Investigator's global satisfaction

| | |
|------------------------|------------------------------------|
| End point title | Investigator's global satisfaction |
| End point description: | |

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Visit 2 / Day 15 | |

| End point values | Polygynax | Miconazole+Placebo | FAS population | |
|------------------------------|-----------------|--------------------|----------------------|--|
| Subject group type | Reporting group | Reporting group | Subject analysis set | |
| Number of subjects analysed | 302 | 309 | 611 | |
| Units: % satisfaction | | | | |
| number (not applicable) | | | | |
| Very Good - Good | 88.3 | 82.1 | 85.2 | |
| Somewhat Good - Somewhat Bad | 8.3 | 13 | 10.7 | |
| Bad - Very Bad | 3.3 | 4.9 | 4.1 | |

Statistical analyses

No statistical analyses for this end point

Secondary: Patient's global satisfaction

| | |
|------------------------|-------------------------------|
| End point title | Patient's global satisfaction |
| End point description: | |

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Visit 2 / Day 15

| End point values | Polygynax | Miconazole+Placebo | FAS population | |
|------------------------------|-----------------|--------------------|----------------------|--|
| Subject group type | Reporting group | Reporting group | Subject analysis set | |
| Number of subjects analysed | 302 | 309 | 611 | |
| Units: % Satisfaction | | | | |
| number (not applicable) | | | | |
| Very Good - Good | 81.8 | 78.2 | 80 | |
| Somewhat Good - Somewhat Bad | 17.1 | 21.1 | 19.2 | |
| Bad - Very Bad | 1 | 0.7 | 0.8 | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

22 days

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|----|
| Dictionary version | 19 |
|--------------------|----|

Reporting groups

| | |
|-----------------------|-----------|
| Reporting group title | Polygynax |
|-----------------------|-----------|

Reporting group description: -

| | |
|-----------------------|----------------------|
| Reporting group title | Miconazole + Placebo |
|-----------------------|----------------------|

Reporting group description: -

| Serious adverse events | Polygynax | Miconazole + Placebo | |
|---|-----------------|----------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 325 (0.31%) | 0 / 328 (0.00%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| Injury, poisoning and procedural complications | | | |
| Patient pregnant exposed to study medication | | | |
| subjects affected / exposed | 1 / 325 (0.31%) | 0 / 328 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 2 %

| Non-serious adverse events | Polygynax | Miconazole + Placebo | |
|---|------------------|----------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 18 / 325 (5.54%) | 5 / 328 (1.52%) | |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 18 / 325 (5.54%) | 5 / 328 (1.52%) | |
| occurrences (all) | 24 | 6 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported